공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

행동 재활 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년)

Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 1008399
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


행동 재활 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년) Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

행동 재활 시장 규모는 2021-2026년의 예측 기간 중 3.5%의 안정된 CAGR로 확대할 것으로 예측됩니다.

COVID-19 팬데믹은 시장에 약간의 마이너스 영향을 미칠 것으로 예측되고 있습니다. 현재 전 세계의 국가가 COVID-19의 심각한 위협에 직면하고 있습니다. 많은 제약회사 및 바이오테크놀러지 기업은 고객으로부터의 높아지는 수요에 대응하기 위해 소독 제품 및 백신 제조에 연구개발 활동을 집중시키고 있습니다. 이 상황으로 인해 대부분의 제약회사 및 바이오테크놀러지 기업은 이 질병의 치료를 위한 새로운 분자 또는 리드를 식별하는 것에 연구개발 부문을 집중시켜 왔습니다.

많은 국가가 이미 COVID-19의 백신을 승인하고 있습니다. 예를 들면 2020년 12월, 세계보건기구(WHO)는 Pfizer/BioNTech의 COVID-19 mRNA 백신의 긴급 사용을 위한 밸리데이션을 세계에 발표했습니다. 2021년 1월에 Nature Reviews Neurology에 게재된 Katya Numbers et al.의 조사 연구에 따르면 치매 등의 정신장애를 가진 사람들은 인지 증상이 보호 절차 및 생활 환경의 준수를 어렵게 하므로 COVID-19 감염의 리스크가 높다고 서술하고 있습니다. 요양시설에서는 바이러스의 확산을 촉진합니다. 또한 치매를 가진 고령자는 치매가 없는 사람보다 심각한 질병 결과를 가질 가능성이 높아집니다. Lewy Body Society에 따르면 치매 및 관련 장애가 있는 사람은 손씻기, 권장되는 물리적 거리를 유지하기, 집에서 COVID-19 증상 감시 등 바이러스의 확산을 막기 위해 만들어진 정부의 가이드라인에 따르는 것이 어렵다고 말하고 있습니다. 보다 더 중증의 치매를 가진 사람은 단기 기억상실과 인지장애로 인해 가이드라인을 이해 또는 기억할 수 없는 경우가 있습니다. 영국 국가 통계청 2020에 따르면 치매와 알츠하이머병은 영국에서 COVID-19에 관련한 사망자 중에서 가장 일반적인 기존 증상(pre-existing conditions)으로 보고되고 있습니다.

또한 COVID-19 팬데믹에 의해 많은 가족이 큰 경제적 부담에 직면하고 있으며, 치료의 옵션을 포기하는 동향이 한층 더 높아지고 있는 것으로 보이고 있습니다. 또한 팬데믹은 신제품 발매에도 악영향을 줄 가능성이 있으며, 이것은 시장의 성장의 가장 현저한 요인으로 추정되고 있습니다. 예를 들면 2020년 4월, Biogen은 데이터 분석의 복잡성과 R&D 리소스에 대한 COVID-19의 영향을 이유로 알츠하이머병과 치매 치료제의 FDA에 대한 제출을 연기했다고 발표했습니다.

행동 재활 시장에 대해 조사했으며, 시장의 개요와 행동 장애 유형별, 의료시설별, 치료법별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 촉진요인
    • 이환율의 상승과 행동 재활의 이용 가능성
    • 온라인 카운셀링의 출현
    • 부분적 입원 프로그램(PHP)의 선호도 증가
    • 정부 구상의 증가
  • 시장 억제요인
    • 행동 장애에 관한 인식의 결여
    • 적절한 상환의 결여
    • 행동 장애가 있는 사람들에 대한 스티그마의 영향
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 행동 장애 유형별
    • 불안장애
    • 기분장애
    • 약물 남용 장애
    • 인격장애
    • 주의결핍장애
  • 헬스케어 시설별
    • 외래 환자 행동 재활
    • 입원 환자 행동 재활
    • 주택 행동 재활
  • 치료법별
    • 카운셀링
    • 투약
    • 지원 서비스
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Acadia Healthcare
    • AAC HOLDINGS INC.
    • Aurora Behavioral Health System
    • Behavioral Health Group
    • Haven Behavioral Healthcare Inc.
    • Magellan Health Inc.
    • Niznik Behavioral Health
    • Promises Behavioral Health
    • Springstone Inc.
    • Universal Health Services Inc.
    • CRC Health
    • American Addiction Centers, Inc.

제7장 시장 기회 및 향후 전망

KSA 21.06.17

The Behavioral Rehabilitation Market is estimated to grow with a steady CAGR of 3.5 % during the forecast period from 2021-2026.

The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the globe are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Owing to the situation, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease.​ Many countries have already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, stated that people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty with following safeguarding procedures and living arrangements in care homes facilitate viral spread. Furthermore, older population with dementia are also more likely to have more severe disease consequences than those without dementia. As per Lewy Body Society, stated that people with dementia and related disorders find harder to follow government guidelines designed to prevent the spread of the virus such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms and staying at home. People with more severe dementia may not be able to understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, stated that dementia and Alzheimer's disease were the most common pre-existing conditions found among deaths involving COVID-19 in United Kingdom.

Furthermore, due to the COVID-19 pandemic, lots of families are facing a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer's and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the age group of 20-29 years, since the past few decades. According to the same source, every year, a large number of people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS) in 2018, one in every five (20%) children and adolescents suffer from mental health disorder at some point in their life. At least, 1 in 10, or about 6 million people suffered serious emotional disturbance at some point in their life.

The treatments for behavioural disorders mainly focuses on behavioural treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioural disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders is targeted toward treating underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression or anxiety. These developments re expected to positively affect market development.

Key Market Trends

Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period

The anxiety disorders are different from normal feelings of anxiousness and involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017, globally, making it the most prevalent mental health or neurodevelopmental disorder. Whereas, the Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Even though anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.

However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, increase in research and development on treatment of anxiety disorders due to overall increasing prevalence of this disorder is expected to drive the market growth over the forecast period.

North America is Expected to Hold the Major Share of the Market Over the Forecast Period

North America is the largest behavioral rehabilitation market in the world, with the United States occupying the major share. The developed countries, including the United States and Canada, have been witnessing a large number of mental health rehabilitation centers opening for the past decade. According to the NIH, in the United States, the prevalence of personality disorder was 9.1%. As per the National Institute of Mental Health, 2018, in the United States, 21.4% of American adults have experienced mood disorders at some point in their lives. It has also been found that there are various new launches in the behavioral health market in North America. For instance, in September 2019, Hackensack Meridian Health launched the first medically integrated urgent care center with behavioral health in the country, with an aim to improve access, better coordinate care, and innovate treatment for people struggling with mental health issues and addiction. Therefore, in addition, favorable government initiatives and a large number of reimbursement options are two of the other factors fueling growth in this region. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps in covering the major part of the treatments. Therefore, all these factors affect the growth of the market.

Competitive Landscape

The market is slightly consolidated with a few major players. Currently, many companies are focusing on the development and introduction of novel products and services into the market which is easily affordable and accessible and entering into strategic collaborations and partnerships to enhance their market positions. Some of the key innovations in the market are: In February 2019, Acadia Healthcare acquired the operations and real estate associated with Whittier Pavilion, a premier behavioral healthcare facility located in Haverhill, Massachusetts, and Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona, and Oklahoma.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence and Availability of Therapies for Behavioral Rehabilitation
    • 4.2.2 Advent of Online Counselling
    • 4.2.3 Increasing Preferences for Partial Hospitalization Programs (PHP)
    • 4.2.4 Rising Government Initiatives
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness Regarding Behavioral Disorders
    • 4.3.2 Lack of Proper Reimbursement
    • 4.3.3 Impact of Stigma on People with Behavioral Disorder
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Behavioral Disorder
    • 5.1.1 Anxiety Disorder
    • 5.1.2 Mood Disorder
    • 5.1.3 Substance Abuse Disorder
    • 5.1.4 Personality Disorder
    • 5.1.5 Attention Deficit Disorder
  • 5.2 By Healthcare Setting
    • 5.2.1 Outpatient Behavioral Rehabilitation
    • 5.2.2 Inpatient Behavioral Rehabilitation
    • 5.2.3 Residential Behavioral Rehabilitation
  • 5.3 By Treatment Method
    • 5.3.1 Counselling
    • 5.3.2 Medication
    • 5.3.3 Support Services
    • 5.3.4 Other Treatment Methods
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Acadia Healthcare
    • 6.1.2 AAC HOLDINGS INC.
    • 6.1.3 Aurora Behavioral Health System
    • 6.1.4 Behavioral Health Group
    • 6.1.5 Haven Behavioral Healthcare Inc.
    • 6.1.6 Magellan Health Inc.
    • 6.1.7 Niznik Behavioral Health
    • 6.1.8 Promises Behavioral Health
    • 6.1.9 Springstone Inc.
    • 6.1.10 Universal Health Services Inc.
    • 6.1.11 CRC Health
    • 6.1.12 American Addiction Centers, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q